GSK-3 Inhibitors: Recent Developments and Therapeutic Potential

    September 2008 in “ Current signal transduction therapy ”
    Shinsuke Kaku, Shigeyuki Chaki, Makoto Muramatsu
    TLDR Drugs that block GSK-3 show promise for treating various diseases.
    Glycogen synthase kinase-3 (GSK-3) was identified in the late 1970s and exists in two isoforms, GSK-3α and GSK-3β, which share high sequence identity. GSK-3 is involved in various cellular functions and has been linked to diseases such as Alzheimer's, diabetes, bipolar disorder, cancer, alopecia, schizophrenia, and circadian rhythm disorders. Due to its role in these diseases, significant efforts have been made to develop selective GSK-3 inhibitors. These inhibitors have shown promising pharmacological effects in cell-based assays and animal models, highlighting their potential as therapeutic agents. The article reviewed the molecular and pharmacological properties of GSK-3, its role in disease pathophysiology, and recent advancements in GSK-3 inhibitor development.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 36 results

      community The truth about Dutasteride (w/ sources)

      in Finasteride/Dutasteride  52 upvotes 3 years ago
      The effectiveness of Dutasteride compared to Finasteride in treating hair loss, with evidence given such as studies and experiences, as well as discussion around whether one should switch from Finasteride to Dutasteride. There is also a discussion on post-Dutasteride syndrome.

      community I had claude create a protocol only using fda approved drugs.

      in Research/Science  3 upvotes 2 weeks ago
      A new hair loss protocol using FDA-approved topical treatments targets eight pathways, potentially improving results by 60-75% compared to the standard 40-50% from oral minoxidil and finasteride. The protocol includes minoxidil, finasteride, tacrolimus, cetirizine, bimatoprost, lithium gluconate, losartan, melatonin, NAC, caffeine, and tretinoin, with a monthly cost of $35-50 in Mexico and $80-150 in the US.

      community The mechanism of androgenic alopecia

      in Research/Science  32 upvotes 3 months ago
      DHT may inhibit hair growth by affecting mitochondrial function, leading to hair follicle miniaturization. Treatments like minoxidil and PP405 may promote hair growth by altering metabolic pathways, potentially counteracting DHT's effects.

    Similar Research

    5 / 807 results